NL
We are pleased to announce that Dr. Marc Vandemeulebroecke has recently been appointed as a visiting professor in the IQ Health Biostatistics Research and Education group. Dr. Vandemeulebroecke is a thought leader in quantitative methods with over 20 years of experience in drug development. Trained as mathematician, statistician and pharmacometrician, he currently heads the Statistical Innovation Group at the pharmaceutical company UCB. Throughout his career in the pharmaceutical industry, he has engaged in methodological research in academic collaborations, and has supported development and approval of numerous new medicines.
The Biostatistics Research Group has a strong research portfolio on innovative methods in clinical research for drug development and regulatory science. Dr. Vandemeulebroecke adds a strong drug development perspective to this portfolio. His expertise will benefit the Radboudumc in translating basic research findings into clinical practice, and aligns well with Radboudumc’s focus on rare diseases, as he was one of the key industry collaborators in obtaining the INVENTS project (HORIZON-HLTH-2023-IND-06). This project aims to innovate the use of advanced modelling to improve the design and value of clinical trials in rare diseases and pediatrics.
As part of his visiting professorship, Dr. Marc Vandemeulebroecke will contribute to the INVENTS project and support dissemination and implementation of research results within the Radboudumc, especially for academic drug development for rare diseases. He will be involved in teaching advanced (MSc) courses related to his area of expertise. As Dr. Vandemeulebroecke puts it: “I look forward very much to contributing to the success of the great IQ Health Biostatistics team at Radboudumc. I am a strong advocate for collaboration and exchange between industry and academia, and this engagement will allow me to pursue this mission even further. I am very grateful for this opportunity.”
Dr. Marc Vandemeulebroecke has been appointed visiting professor for three years, from 01-01-2025 to 31-12-2027.